Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in …

K Kurose, E Sugiyama, Y Saito - Drug metabolism and …, 2012 - jstage.jst.go.jp
Drug lag, recently discussed extensively in Japan, can be divided into two phases: clinical
development time and application review time. The former factor is still an important problem …

Pharmacokinetics of caffeine: A systematic analysis of reported data for application in metabolic phenotyping and liver function testing

J Grzegorzewski, F Bartsch, A Köller… - Frontiers in …, 2022 - frontiersin.org
Caffeine is by far the most ubiquitous psychostimulant worldwide found in tea, coffee, cocoa,
energy drinks, and many other beverages and food. Caffeine is almost exclusively …

Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk

N Božina, V Bradamante, M Lovrić - Archives of Industrial Hygiene and …, 2009 - sciendo.com
The polymorphic P450 (CYP) enzyme superfamily is the most important system involved in
the biotransformation of many endogenous and exogenous substances including drugs …

Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations

A LLerena, MEG Naranjo… - Expert opinion on …, 2014 - Taylor & Francis
Introduction: The frequency of CYP2D6 alleles, related to either a lack of or increased
enzymatic activity, which may lead to poor metabolism (PM) or ultrarapid metabolism (UM) …

Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization

J Kevin Hicks, JJ Swen, A Gaedigk - Current drug metabolism, 2014 - ingentaconnect.com
The cytochrome P450 2D6 (CYP2D6) enzyme contributes to the metabolism and/or
bioactivation of approximately 25% of clinically used drugs. The CYP2D6 gene locus is …

Inconsistency in race and ethnic classification in pharmacogenetics studies and its potential clinical implications

F Zhang, J Finkelstein - Pharmacogenomics and personalized …, 2019 - Taylor & Francis
Introduction Racial and ethnic categories are frequently used in pharmacogenetics literature
to stratify patients; however, these categories can be inconsistent across different studies. To …

Genetic polymorphisms of drug‐metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population

K Arvanitidis, G Ragia, M Iordanidou… - Fundamental & …, 2007 - Wiley Online Library
The aim of the present study was to determine the prevalence of the most common allelic
variants of the polymorphic cytochrome P450 (CYP) enzymes CYP2D6, CYP2C9, CYP2C19 …

Pharmacogenetics and forensic toxicology: A new step towards a multidisciplinary approach

N Di Nunno, M Esposito, A Argo, M Salerno, F Sessa - Toxics, 2021 - mdpi.com
Pharmacogenetics analyzes the individual behavior of DNA genes after the administration of
a drug. Pharmacogenetic research has been implemented in recent years thanks to the …

Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs

T Hirota, S Eguchi, I Ieiri - Drug metabolism and pharmacokinetics, 2013 - jstage.jst.go.jp
Human cytochrome P450 (CYP) is a superfamily of hemoproteins which oxidize a number of
endogenous compounds and xenobiotics. The human CYP2C subfamily consists of four …

The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance

J Rosemary, C Adithan - Current clinical pharmacology, 2007 - ingentaconnect.com
CYP2C9 and CYP2C19 are important drug metabolizing enzymes and together metabolize
about 18% of currently available drugs. Some of the important groups of drugs that are …